|Day Low/High||4.50 / 4.75|
|52 Wk Low/High||4.10 / 10.50|
Presentation Scheduled for Monday, February 13, 2017 at 9:00am ET
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of TG Therapeutics, Inc.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased TG Therapeutics, Inc.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
Presentation Scheduled for Thursday, January 12, 2017 at 10:30am PST
Phase 2 trial of TGR-1202 plus ibrutinib designed to target B-cell receptor (BCR) pathway at multiple points in DLBCL patients relapsed from or ineligible for stem cell transplant
Investors in TG Therapeutics Inc saw new options begin trading this week, for the August 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Combination treatment resulted in 95% ORR in patients with High-Risk CLL, the patient population being evaluated in the Phase 3 GENUINE Trial
Top-line data expected first half 2017
Preclinical work may offer rationale for the differentiated activity and safety effects of TGR-1202
Investor Reception to be Held on Monday December 5, 2016 at 8:00pm PT at the Marriott Gaslamp Hotel with Presentations by Leading Clinical Investigators
Investors in TG Therapeutics Inc saw new options become available this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new January 2017 contracts and identified one put and one call contract of particular interest.
No safety concerns identified; UNITY-CLL Phase 3 trial to continue as planned
Investor Conference Call to be Held Today, Monday, November 7, 2016 at 8:30am ET
Investor Conference Call to be held Monday, November 7, 2016 at 8:30am ET
Investor Reception to be Held on Monday, December 5, 2016 at 8:00pm PT at the Marriott Gaslamp Hotel with Presentations by Leading Clinical Investigators